{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T05:24:33Z","timestamp":1741238673753,"version":"3.38.0"},"reference-count":6,"publisher":"JLE","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Dermatol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1684\/ejd.2019.3511","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T15:24:28Z","timestamp":1696865068000},"page":"107-108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Erythema multiforme-like rash upon anti-melanoma therapy with BRAF and MEK inhibitors"],"prefix":"10.1684","volume":"29","author":[{"given":"Franziska","family":"Gr\u00e4n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Goebeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Gesierich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","published-online":{"date-parts":[[2019,5,6]]},"reference":[{"key":"3511_CR1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1634\/theoncologist.2012-0333","volume":"18","author":"ME Lacouture","year":"2013","unstructured":"Lacouture ME, Duvic M, Hauschild A, et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 2013; 18: 314\u201322.","journal-title":"Oncologist"},{"key":"3511_CR2","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1007\/s00105-013-2733-8","volume":"65","author":"R Gutzmer","year":"2014","unstructured":"Gutzmer R, Hassel JC, Kahler KC, et al. Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors. Hautarzt 2014; 65: 582\u20139.","journal-title":"Hautarzt"},{"key":"3511_CR3","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(15)00087-X","volume":"16","author":"JJ Grob","year":"2015","unstructured":"Grob JJ, Amonkar MM, Karaszewska B, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol 2015; 16: 1389\u201398.","journal-title":"Lancet Oncol"},{"key":"3511_CR4","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","volume":"386","author":"GV Long","year":"2015","unstructured":"Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015; 386: 444\u201351.","journal-title":"Lancet"},{"key":"3511_CR5","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binime-tinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol 2018; 19: 1315\u201327.","journal-title":"Lancet Oncol"},{"key":"3511_CR6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1177\/1758834014566428","volume":"7","author":"SJ Welsh","year":"2015","unstructured":"Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol 2015; 7: 122\u201336.","journal-title":"Ther Adv Med Oncol"}],"container-title":["European Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1684\/ejd.2019.3511.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1684\/ejd.2019.3511\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1684\/ejd.2019.3511.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.jle.com\/10.1684\/ejd.2019.3511","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:23:53Z","timestamp":1741191833000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jle.com\/10.1684\/ejd.2019.3511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":6,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["3511"],"URL":"https:\/\/doi.org\/10.1684\/ejd.2019.3511","relation":{},"ISSN":["1952-4013"],"issn-type":[{"type":"electronic","value":"1952-4013"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"6 Mai 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}